ArticleAmerican journal of translational research2026
Effect of circulating irisin level on clinical outcome in obesity-associated atherosclerosis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the association between circulating irisin levels, metabolic profiles, and clinical outcomes in obesity-associated atherosclerosis.
methodsThis retrospective study included 220 patients admitted to the Department of Cardiology between January 2022 and January 2025, stratified into four groups based on body mass index and atherosclerosis status. Fasting blood samples were analyzed for serum irisin, glucose, HbA1c, insulin (HOMA-IR), and lipid profiles, including small dense LDL. Echocardiography was performed to assess cardiac structure and function, while carotid ultrasonography was used to quantify intima-media thickness and plaque burden; severe atherosclerosis was defined as a plaque area > 30 mm
resultsSerum irisin levels were highest in normal-weight controls and progressively decreased across the overweight and atherosclerotic groups (P < 0.05). Concomitantly, fasting glucose, HbA1c, and HOMA-IR increased in a stepwise manner, with the most significant derangements observed in overweight patients with atherosclerosis. Dyslipidemia was characterized by elevated total cholesterol, LDL-C, and triglycerides, along with reduced HDL-C, particularly in groups with vascular disease. Cardiac structural remodeling was evident, with progressive increases in left ventricular (LV) mass and left atrial size, reductions in ejection fraction and global longitudinal strain, and worsening diastolic indices (all P < 0.001). The incidence of MACE increased from 3.6% in Group A to 45.5% in Group D (P < 0.001). Cox regression analysis identified age, BMI, diabetes, and LDL-C as independent risk factors, whereas each 1 ng/mL increase in irisin was associated with a 26% reduction in MACE risk. Logistic regression further revealed that low irisin was the strongest predictor of severe atherosclerosis (OR 0.128, 95% CI 0.058-0.283, P < 0.001).
conclusionLow circulating irisin is an independent predictor of severe atherosclerosis and adverse cardiovascular outcome in patients with obesity-associated vascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.